All stock lists
Unlock the score
Gerresheimer AG (Deutsche Börse:GXI.DE)
DE · Delayed Price · Currency is EUR
Also listed: GRRMF, GXI.SWHealthcare · Medical - Instruments & Supplies
33.00+1.66 (+5.30%)
Market cap
$1.14B
Insider Score
Health Score
Listed since
Jun 11, 2007
Website
Insider Score
/ 100
GXI.DE Insider Score
Gerresheimer AG has a live Insider Score.
Scored on 7 qualifying trades from 1 insider in the last 90 days.
Financial Health Score
Fair
From GXI.DE’s reported statements · Q1 2026 (trailing 12 months)
Profitability1 / 20
Loses money on what it sells.
- Revenue
- $2.28B
- Net income
- -$400.6M
- Net margin
- -17.6%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $2.21B
- Cash
- $167.6M
- Net debt / EBITDA
- 8.56x
Liquidity8 / 20
Covers near-term obligations, without much room.
- Current assets
- $1.53B
- Current liabilities
- $1.43B
- Current ratio
- 1.07
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $261.6M
- Free cash flow
- $369.5M
- FCF margin
- 16.2%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 34.5M
- Share growth (1y)
- 0.0%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
GXI.DE Income Statement
| Fiscal Period | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Period Ending | Feb 28, 2026 | Nov 30, 2025 | Aug 31, 2025 | May 31, 2025 | Feb 28, 2025 | Nov 30, 2024 |
| Revenue | 474.94 M | 639.49 M | 560.68 M | 600.65 M | 520.05 M | 568.87 M |
| Revenue Growth (YoY) | -8.68 % | 12.41 % | 12.47 % | 19.56 % | 11.57 % | 4.35 % |
| Cost of Revenue | 425.68 M | 637.72 M | 421.79 M | 442.82 M | 393.30 M | 387.19 M |
| Gross Profit | 49.26 M | 1.78 M | 138.89 M | 157.83 M | 126.75 M | 181.68 M |
| SG&A Expense | 86.74 M | 129.19 M | 100.98 M | 105.31 M | 103.17 M | 60.16 M |
| R&D Expense | 8.86 M | 71.05 M | 5.57 M | 3.16 M | 6.12 M | 6.89 M |
| Operating Expenses | 95.61 M | 325.21 M | 90.57 M | 107.16 M | 111.63 M | 120.12 M |
| Operating Income | -46.34 M | -323.43 M | 48.32 M | 50.67 M | 15.12 M | 61.56 M |
| Pretax Income | -79.60 M | -318.58 M | -15.01 M | 28.78 M | -25.32 M | 47.58 M |
| Tax Provision | 27.93 M | 11.99 M | 2.74 M | 11.16 M | -7.83 M | 9.29 M |
| Net Income | -98.32 M | -306.63 M | -12.70 M | 17.02 M | -18.01 M | 37.04 M |
| EPS (Basic) | -2.85 | -8.88 | -0.37 | 0.49 | -0.52 | 1.07 |
| EPS (Diluted) | -2.85 | -8.88 | -0.37 | 0.49 | -0.52 | 1.07 |
| Shares Outstanding | 34.54 M | 34.54 M | 34.54 M | 34.54 M | 34.54 M | 34.54 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.